Literature DB >> 29503244

Larotrectinib in TRK fusion-positive cancers.

Talha Khan Burki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29503244     DOI： 10.1016/S1470-2045(18)30190-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

Review 1.  Interstitial Deletions Generating Fusion Genes.

Authors:  Ioannis Panagopoulos; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

2.  Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib.

Authors:  Musa Alharbi; Nahla Ali Mobark; Ali Abdullah O Balbaid; Fatmah A Alanazi; Wael Abdel Rahman Aljabarat; Eman A Bakhsh; Shakti H Ramkissoon; Malak Abedalthagafi
Journal:  JCO Precis Oncol       Date:  2020-06-30

Review 3.  The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer.

Authors:  Carlotta Antoniotti; Elena Ongaro; Alfredo Falcone; Chiara Cremolini
Journal:  Int J Mol Sci       Date:  2018-08-05       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.